Noticias y vídeos - VERITAS PHARMA INC VRTHF

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - Veritas Pharma Inc.'s (CSE: VRT) (OTC: VRTHF) (Frankfurt: 2VP) ("Veritas" or the "Company") is pleased to announce that its fully owned subsidiary the Sechelt Organic Marijuana Corp. has completed the sale of its property located in Sechelt, BC, to Lis Holdings Ltd. for cash consideration of $350,000. This property was originally purchased in February 2015 with plans to construct a medical cannabis production facility under the...

VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce that it has reached a settlement with Arbutus Biopharma Corporation (“Arbutus”) with respect to the litigation commenced by Arbutus. The claims relate to a commercial lease space, which Veritas no longer believes is necessary for its R&D. As a part of the mutual settlement, no party has admitted any liability and there...

VANCOUVER, British Columbia, July 10, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has completed the sale of its interest in 3 Carbon Extractions Inc. (“3 Carbon”) to Mr. Yari Nieken for cash consideration of $375,000. In April of 2018 Veritas Pharma announced the acquisition of 50% of the issued and outstanding shares of 3 Carbon. 3 Carbon is a private corporation that is in the business of...

VANCOUVER, British Columbia, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps to restructure and rebuild Cannevert Therapeutics Ltd. (“CTL”), a wholly owned subsidiary of Veritas. This restructuring includes both permanent and temporary cutbacks of the number of staff currently working with CTL with the exception of senior members of the research team. The company’s...

SAN JUAN, Puerto Rico, May 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), is pleased to announce the completion of its clinical trial on its lead cannabis treatment (“CTL-X”) for acute pain. The clinical trial was designed as a randomized, double-blinded, cross-over trial and tested the efficacy of vaporized CTL-X for the treatment of acute pain in healthy adult...

VANCOUVER, British Columbia, March 27, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce corporate highlights and to communicate the company’s direction for the year ahead. 2018 and the first quarter of 2019 has been a transition period for Veritas Pharma, as the company has matured from being purely engaged in research and development to establishing a viable option for cannabis production in...

VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal proceedings against Liht Cannabis Corp. (" Liht ") (formerly Marapharm Ventures Inc.) to recover a loan made by Veritas to Liht in the amount of $1,000,000.00 plus accrued interest. The loan is in default and Veritas has made demand for repayment but Liht has refused to make...

VANCOUVER, British Columbia, March 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim and is commencing legal proceedings against Liht Cannabis Corp. (" Liht ") (formerly Marapharm Ventures Inc.) to recover a loan made by Veritas to Liht in the amount of $1,000,000.00 plus accrued interest. The loan is in default and Veritas has made demand for repayment but Liht has refused to make...

SAN JUAN, Puerto Rico, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico LLC, a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), today announced the dosing of the first adult volunteer in its clinical trial of their lead cannabis product (“CTL-X”) for the treatment of acute pain. The randomized, double-blinded crossover trial will assess the safety, tolerability and efficacy of CTL-X as a single dose vaporized challenge in...

VANCOUVER, British Columbia, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into an agreement with TG Initiatives Ltd., to purchase a commercial processing facility for hemp and cannabis products(“asset”), that asset is capable of making a variety of hemp and cannabis products including edibles for human and animal use. Additionally, this asset provides the...

VANCOUVER, British Columbia, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces the resignation of its President, CEO and Director, Dr. Lui Franciosi. Company Interim CFO, Mr. Peter McFadden will fill the executive roles in the interim until a qualified replacement is found. Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X...

SAN JUAN, Puerto Rico, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma, Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas”), in partnership with the Institute for Medical Cannabis (“IMC”) and the Fundación de Investigación (“FDI”) were approved this past Friday for an Investigation License from the Commonwealth of Puerto Rico Medicinal Cannabis Regulatory Board allowing clinical evaluation of their lead...

VANCOUVER, British Columbia, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a consolidation of its issued and outstanding common shares at a ratio of one (1) post-consolidation common share for every ten (10) pre-consolidation common shares (the “Consolidation”) The common shares will commence trading on the Canadian Securities Exchange on a consolidated basis on...

VANCOUVER, British Columbia, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding ( “MOU” ) with Santa Marta Gold Holdings Ltd. ( “Santa Marta” ) where both companies will share the intellectual property ( “IP” ) jointly developed as part of a proposed agreement that outlines a medical cannabis research collaboration. Under the...

VANCOUVER, British Columbia, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that the Company has entered into a share exchange agreement with three separate individuals for the issuance of 14,583,333, 14,583,333 and 12,500,000 common shares of Veritas at $0.12 per share in exchange for their 700,000, 700,000, and 600,000 shares at $2.50 per share, respectively, of the private cannabis...

VANCOUVER, British Columbia, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce the appointment of Blair Lowther as the Corporate Secretary of the Company. Blair is a corporate lawyer with many years of experience working with public companies, particularly in the cannabis industry. Blair is excited to help ensure the continued integrity of the Company’s governance framework,...

VANCOUVER, British Columbia, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that it has entered into a binding share purchase agreement (the “Agreement” ) to sell 100% of the outstanding common shares of Sechelt Organic Marijuana Inc. ( “Sechelt” ) to Leis Industries Limited ( “Leis” ). The Company previously announced on September 13, 2018 that it had entered into a...

VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce that, despite the catastrophic events in Puerto Rico related to Hurricane Maria in the fall of 2017, and the restrictions imposed by US Federal Government’s conservative position on cannabis over the last year, it is now preparing to commence human trials to test its lead cannabis product ( “CTL-X” )....

VANCOUVER, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce the Closing of the Private Placement announced September 20, 2018. The Company was able to raise $1.56 million through the issue of 8,210,527 shares of common stock of the Company. The funds raised were used to acquire a 25% interest in a 10,000 square foot cannabis growing facility located in Kelowna British...

VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) ( “ Veritas ” or the “Company”) is pleased to announce a $1.25 million investment to acquire a 25% interest in a 10,000 square foot cannabis growing facility located in Kelowna, British Columbia, and licensed under the Health Canada Access to Cannabis for Medical Purposes Regulations ( “ACMPR” ) The investment is by way of acquiring shares in a holding company...